The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology …

…, E Pentsova, T Cloughesy, FM Iwamoto… - Neuro …, 2017 - academic.oup.com
Background. The Macdonald criteria and the Response Assessment in Neuro-Oncology (RANO)
criteria define radiologic parameters to classify therapeutic outcome among patients …

Primary dural lymphomas: a review

FM Iwamoto, LE Abrey - Neurosurgical focus, 2006 - thejns.org
✓Primary dural lymphoma (PDL) is a rare subtype of primary central nervous system
lymphoma (PCNSL) that arises from the dura mater and differs biologically from other CNS …

Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a …

…, S Brem, JL Campian, JE Trusheim, FM Iwamoto… - JAMA …, 2023 - jamanetwork.com
… Dr Iwamoto reported receiving grants from Northwest Biotherapeutics and serving on the
steering committee of this trial during the conduct of the study and receiving personal fees from …

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

…, JN Bruce, YM Saenger, P Sims, FM Iwamoto… - Nature medicine, 2019 - nature.com
Immune checkpoint inhibitors have been successful across several tumor types; however,
their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where <10% of …

[HTML][HTML] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

…, M Salacz, S Taylor, SD D'Andre, FM Iwamoto… - Journal of translational …, 2018 - Springer
Background Standard therapy for glioblastoma includes surgery, radiotherapy, and
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

PH Gutin, FM Iwamoto, K Beal, NA Mohile… - International Journal of …, 2009 - Elsevier
PURPOSE: Preclinical studies suggest that inhibition of vascular endothelial growth factor (VEGF)
improves glioma response to radiotherapy. Bevacizumab, a monoclonal antibody …

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

L Nayak, FM Iwamoto, A LaCasce… - Blood, The Journal …, 2017 - ashpublications.org
Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma
(PTL) are rare extranodal large B-cell lymphomas with similar genetic signatures. There are …

Scale to predict survival after surgery for recurrent glioblastoma multiforme

…, N Olsen Bailey, TN Kreisl, FM Iwamoto… - Journal of clinical …, 2010 - ascopubs.org
Purpose Despite initial treatment with surgical resection, radiotherapy, and chemotherapy,
glioblastoma multiforme (GBM) virtually always recurs. Surgery is sometimes recommended …

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

FM Iwamoto, LE Abrey, K Beal, PH Gutin… - Neurology, 2009 - AAN Enterprises
Background: Bevacizumab has recently been approved by the US Food and Drug
Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and …

Primary CNS lymphoma with intraocular involvement: international PCNSL collaborative group report

…, N Laperriere, E Thiel, N Doolittle, FM Iwamoto… - Neurology, 2008 - AAN Enterprises
Objective: To describe the demographics, diagnostic details, therapeutic management, and
outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement. Methods…